- Home
- IGMS vs ATRC Comparison
IGMS vs ATRC Comparison
Compare IGMS & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ATRC
- Stock Information
- Founded
- IGMS 1993
- ATRC 2000
- Country
- IGMS United States
- ATRC United States
- Employees
- IGMS N/A
- ATRC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- IGMS Health Care
- ATRC Health Care
- Exchange
- IGMS Nasdaq
- ATRC Nasdaq
- Market Cap
- IGMS 962.1M
- ATRC 1.1B
- IPO Year
- IGMS 2019
- ATRC 2005
- Fundamental
- Price
- IGMS $9.47
- ATRC $35.03
- Analyst Decision
- IGMS Hold
- ATRC Strong Buy
- Analyst Count
- IGMS 8
- ATRC 9
- Target Price
- IGMS $14.63
- ATRC $43.11
- AVG Volume (30 Days)
- IGMS 238.9K
- ATRC 728.7K
- Earning Date
- IGMS 11-08-2024
- ATRC 10-29-2024
- Dividend Yield
- IGMS N/A
- ATRC N/A
- EPS Growth
- IGMS N/A
- ATRC N/A
- EPS
- IGMS N/A
- ATRC N/A
- Revenue
- IGMS $2,918,000.00
- ATRC $447,573,000.00
- Revenue This Year
- IGMS $298.54
- ATRC $17.75
- Revenue Next Year
- IGMS N/A
- ATRC $13.44
- P/E Ratio
- IGMS N/A
- ATRC N/A
- Revenue Growth
- IGMS 57.64
- ATRC 17.56
- 52 Week Low
- IGMS $4.72
- ATRC $18.94
- 52 Week High
- IGMS $22.50
- ATRC $43.00
- Technical
- Relative Strength Index (RSI)
- IGMS 28.30
- ATRC 60.08
- Support Level
- IGMS $10.91
- ATRC $33.08
- Resistance Level
- IGMS $16.32
- ATRC $38.34
- Average True Range (ATR)
- IGMS 1.53
- ATRC 1.47
- MACD
- IGMS -0.79
- ATRC -0.01
- Stochastic Oscillator
- IGMS 0.80
- ATRC 67.13
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.